Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy.
about
Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission.Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival.Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan.Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia.Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis.Separating graft-versus-tumor from graft-versus-host reactions.Imatinib mesylate, the first molecularly targeted gene suppressor.The war on cancer: a report from the front linesSimilar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors.Steroid-Refractory Acute GVHD: Predictors and Outcomes.Low-intensity transplant regimens facilitate recruitment of donor-specific regulatory T cells that promote hematopoietic engraftment.Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcomeReduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era.Nonmyeloablative stem cell transplantation as immunotherapy for kidney cancer and other metastatic solid tumors.Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting.Allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia: similar outcomes regardless of donor type.Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning.Radioimmunotherapy and stem-cell transplantation in the treatment of aggressive B-cell lymphoma.Reduced intensity conditioning and allogeneic stem cell transplantation in childhood malignant and nonmalignant diseases.Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.Non-myeloablative allogeneic hematopoietic stem cell transplantation.Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma.Pretransplant comorbidities maintain their impact on allogeneic stem cell transplantation outcome 5 years posttransplant: a retrospective study in a single german institution.MDS disease characteristics, not donor source, predict hematopoietic stem cell transplant outcomes.Older patients with acute myeloid leukemia.Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors.Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike.Promising role of reduced-toxicity hematopoietic stem cell transplantation (PART-I).Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation.Reduced intensity transplantation for primary immunodeficiency disorders.Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML.Allogeneic stem cell transplantation for chronic myeloid leukemia resistant to tyrosine kinase inhibitors.Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies.Skin cancer after nonmyeloablative hematopoietic cell transplantation.Allo-SCT using reduced-intensity conditioning against advanced pancreatic cancer: a Japanese survey.Reduced intensity conditioning regimen followed by glycosylated G-CSF mobilized PBSCT in patients with solid tumors and malignant lymphomas.Immune reconstitution following reduced-intensity transplantation with cladribine, busulfan, and antithymocyte globulin: serial comparison with conventional myeloablative transplantation.A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease.Prophylactic red blood cell exchange for ABO-mismatched hematopoietic progenitor cell transplants.
P2860
Q30408294-2E562AAD-E71D-4DA9-B524-A44BA3156738Q33756719-EB04C4E3-92DF-46A9-B06A-9BEF56C51688Q33813439-39B13960-ACCB-4AF8-9375-3453A55F184CQ33841438-D80A7798-4583-4346-8889-36A73C6262FEQ34185528-8C366C5F-0164-470D-8022-651CC86C850DQ34360641-4CD04F01-E7A8-4472-832C-8FF802D4256CQ34769849-975C702B-22DE-4574-818D-486113A6C661Q34975667-D92F44A3-B4A1-4712-886F-1CACF05094A8Q35103643-4AE81840-5BAB-4667-89C7-76D63D8A00FCQ35129248-E92328CB-3478-4235-BFE3-5A0BBC481880Q35550596-1CE32350-EA7D-47B5-BA3F-1756ED8783E0Q35850195-86462BFF-7DBE-4428-8B82-28C92DF2FC48Q35925072-58FC4943-BD97-4D83-882C-B9460D1339A0Q35953410-8EDF5534-4761-4790-B60F-0C6E38680326Q36304574-AD10131B-6FB9-4117-A64B-CF07524AC26BQ36341861-951AA185-B523-4370-B13F-97B8675284D6Q36530726-7E3040D2-8368-42DB-A373-B299240D4F16Q36548358-0999F42E-C0DB-47B0-84A7-79A67BEFEAEDQ36950052-51E7FD58-743A-46E5-8602-11A7F1FC48C9Q37014122-443F21EA-1EC7-473D-B89D-EE81732F0F8CQ37159533-0601EDD2-68CD-4CB8-9710-B0D87CC6A90EQ37308127-76CDD1B2-DC06-409A-9B2C-2F4672390047Q37490193-3A891422-DF45-48FA-B8BF-C11C0918ADD0Q37657429-42079147-5DE7-444E-98D7-085A87BC837FQ37739020-84B95C41-8056-4A42-8E76-9EDF1F91B1FFQ37810969-B91FC752-64F3-45C7-881D-91339CE9438FQ37853793-40F6EC99-1E6B-4585-BF04-CA651893168EQ37863461-5F2FE396-4D62-4532-9916-A9F322D644F0Q38029953-36E041D2-1EE1-46A5-9285-8E72FC05EFB9Q38488058-656D6828-1651-40EE-A690-C0EC08DCCFC2Q38912369-C91B2CFE-1580-4106-81B9-C9955E3085E7Q39137552-25A90E27-F3E5-4D1F-BD42-51E3FD095596Q39464336-3D891AD3-3CC7-46A1-B057-70E0F36987E9Q42165336-C54F933C-2AB0-4CF8-8BCC-DA30D9FE49F3Q42496514-E836B76D-78DA-438D-9422-088AF385527DQ43582944-FDFE777B-CD57-40AF-876A-B1F8C68B14CFQ44119537-D0AE1C78-406A-4CCE-8D49-6856C2226778Q44571777-8A60CDB6-5368-4014-9B9F-3CCE0D12EC02Q44780698-7DA649A8-714D-4096-B536-634FD35AE209Q46168868-DE78E826-4F45-4DB8-AF58-5F81CF5615CA
P2860
Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy.
description
2000 nî lūn-bûn
@nan
2000 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Harnessing graft-versus-malign ...... gy for adoptive immunotherapy.
@ast
Harnessing graft-versus-malign ...... gy for adoptive immunotherapy.
@en
Harnessing graft-versus-malign ...... gy for adoptive immunotherapy.
@nl
type
label
Harnessing graft-versus-malign ...... gy for adoptive immunotherapy.
@ast
Harnessing graft-versus-malign ...... gy for adoptive immunotherapy.
@en
Harnessing graft-versus-malign ...... gy for adoptive immunotherapy.
@nl
prefLabel
Harnessing graft-versus-malign ...... gy for adoptive immunotherapy.
@ast
Harnessing graft-versus-malign ...... gy for adoptive immunotherapy.
@en
Harnessing graft-versus-malign ...... gy for adoptive immunotherapy.
@nl
P2093
P2860
P1476
Harnessing graft-versus-malign ...... gy for adoptive immunotherapy.
@en
P2093
Anderlini P
Champlin R
Gajewski J
Kornblau S
Molldrem J
P2860
P356
10.1046/J.1365-2141.2000.02196.X
P407
P577
2000-10-01T00:00:00Z